![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, September 28, 2017 8:19:59 AM
• 10/27/17 Wayne State University presentation
http://www.professionalabstracts.com/ectrims2017/iplanner/#/grid
Credit tttav66 ihub poster: "Then scroll down to Friday the 27th, and look at the row at 14:00. You'll see "Parallel Session 14: Remyelination: from biology to clinical trials". Click that and you will see a list. Go down to Session 238 and click that. There you will see:"
238 - Sigma 1 receptor agonists as potential protective and reparative therapy in multiple sclerosis
R.P. Lisak, L. Nedelkoska, J.A. Benjmains Neurology, Wayne State University School of Medicine, Detroit, MI, United States
The complete abstract will be published on 15 October 2017.
• The Parkinson's and Disease Therapeutics Conference
October 30, 2017
"The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development."
She has one of only 8 posters at this year's event: Veronica Francardo, PhD
Lund University
ANAVEX 2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism
https://www.michaeljfox.org/research/parkinsons-therapeutics-conference.html?navid=pd-therapeutics-conf
• 11/1-11/4/17 CTAD Boston
LBP33: Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease
• Neuroscience 2017 Conference
November 13, 2017 from 3-4p
Topic:
370.07 / C20 - Efficacy of ANAVEX 2-73, a Sigma-1 receptor agonist, in the MECP2 mouse model of Rett syndrome; Authors: J. S. SPROUSE, N. REBOWE, D. KLAMER, C. MISSLING;
Anavex Life Sci., New York, NY
https://www.abstractsonline.com/pp8/#!/4376/presentation/16595
• Neuroscience 2017 Conference
November 14, 2017 from 2-3p
http://www.abstractsonline.com/pp8/#!/4376/presentation/28724
572.22 / S4 - ANAVEX 2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism
Authors
*V. FRANCARDO1, F. BEZ1, J. S. SPROUSE2, C. MISSLING2, A. CENCI1;
1Lund Univ., Lund, Sweden; 2Anavex Life Sci., New York, NY
"Conclusion: Our results reveal that ANA 2-73 ameliorates motor deficits in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts noticeable neurorestorative effects on the damaged nigrostriatal dopamine system. Further experiments are now ongoing to elucidate the mechanisms underlying these effects."
[Lastly, someone on the board had posted a link to another conference in Spain? in MAY 2018? that we'd copied/pasted the below abstract from Dr Francardo as well. However I can no longer find the link to the abstract/conference to cite the below, will need to reconfirm:
"Using the same animal model of PD as in our previous study (i.e. intrastriatal 6-OHDA mouse model), we investigated the potential neurorestorative effects of ANAVEX 2-73, a compound with activity at both Sigma-1 and muscarinic receptors that is currently being tested in people affected by Alzheimer´s disease. Our results reveal that ANAVEX 2-73 is able to ameliorate parkinsonian motor symptoms in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts neuroprotective/neurorestorative effects on the nigrostriatal dopamine system."
Listing of Dr Veronica Francardo's published work (credit to poster neiu for the link): http://portal.research.lu.se/portal/en/persons/veronica-francardo(9c206658-28b7-4a7c-a4e3-2f199ca7618a)/publications.html ]
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM